KR100671366B1 - 탈리도마이드의 제약 조성물 및 투여 형태 - Google Patents
탈리도마이드의 제약 조성물 및 투여 형태 Download PDFInfo
- Publication number
- KR100671366B1 KR100671366B1 KR1020057008631A KR20057008631A KR100671366B1 KR 100671366 B1 KR100671366 B1 KR 100671366B1 KR 1020057008631 A KR1020057008631 A KR 1020057008631A KR 20057008631 A KR20057008631 A KR 20057008631A KR 100671366 B1 KR100671366 B1 KR 100671366B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- thalidomide
- dosage form
- cancer
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
캡슐화 탈리도마이드 투여량 | ||
캡슐 크기 | 캡슐 무게 (mg) | 탈리도마이드 용량 (mg) |
#0 | 500 | 200 |
#2 | 250 | 100 |
#4 | 125 | 50 |
물질 | 중량% | 양(mg/정제) | 양(kg/배치) |
탈리도마이드 | 40.0 % | 200 mg | 16.80 kg |
전젤라틴화 옥수수 전분, NF | 59.5 % | 297.5 mg | 24.99 kg |
마그네슘 스테아레이트 | 0.5 % | 2.5 mg | 0.21 kg |
전체 | 100.0 % | 500 mg | 42.00 kg |
물질 | 중량% | 양(mg/정제) | 양(kg/배치) |
탈리도마이드 | 40 % | 100.00 | 20.00 |
미결정 셀룰로오스,NF | 53.5 % | 133.75 | 26.75 |
플루오로닉 F-68 표면활성제 | 4.0 % | 10.00 | 2.00 |
크로스카멜로스 소듐 타입 A, NF | 2.0 % | 5.00 | 1.00 |
마그네슘 스테아레이트,NF | 0.5 % | 1.25 | 0.25 |
전체 | 100.0 % | 250.00 mg | 50.00 mg |
물질 | 중량% | 양(mg/정제) | 양(kg/배치) |
탈리도마이드 | 12.5 % | 50.0 | 7.50 |
미결정 셀룰로오스 | 15.0 % | 60.0 | 9.00 |
콜리돈 90F USP1 | 3.0 % | 12.0 | 1.80 |
스테아르산 NF | 1.0 % | 4.0 | 0.60 |
콜로이드성 이산화규소 | 0.2 % | 0.8 | 0.12 |
크로스포비돈 NF | 4.0 % | 16.0 | 2.40 |
무수 락토오스 NF | 64.3 % | 257.3 | 38.58 |
전체 | 100.0 % | 400.0 mg | 60.00 kg |
1 또한, 바스프의 포비돈(Povidone) 90F USP로 제조. |
Claims (39)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 50 mg의 탈리도마이드 및 74 mg의 전젤라틴화 옥수수 전분의 균일한 혼합물을 포함하는 4호 크기 캡슐 형태의 단일 단위 투여 형태.
- 삭제
- 제24항에 있어서, 마그네슘 스테아레이트를 추가로 포함하는 투여 형태.
- 제26항에 있어서, 마그네슘 스테아레이트가 1 mg의 양으로 존재하는 투여 형태.
- 제24항에 있어서, 내용물의 중량이 125 mg인 투여 형태.
- 내용물의 중량이 250 mg 중량이며, 100 mg의 탈리도마이드 및 전젤라틴화 옥수수 전분을 포함하는 2호 크기 캡슐 형태의 단일 단위 투여 형태.
- 제29항에 있어서, 마그네슘 스테아레이트를 추가로 포함하는 투여 형태.
- 200 mg의 탈리도마이드 및 297.5 mg의 전젤라틴화 옥수수 전분의 균일한 혼합물을 포함하는 0호 크기 캡슐 형태의 단일 단위 투여 형태.
- 삭제
- 제31항에 있어서, 마그네슘 스테아레이트를 추가로 포함하는 투여 형태.
- 제33항에 있어서, 마그네슘 스테아레이트가 2.5 mg의 양으로 존재하는 투여 형태.
- 제31항에 있어서, 내용물의 중량이 500 mg인 투여 형태.
- 제24항, 제26항 내지 제31항 및 제33항 내지 제35항 중 어느 한 항의 단일 단위 투여 형태를 포함하는, 나병, 만성 이식편대숙주병, 류마티스 관절염, 사르코이드증, 염증성 상태, 염증성 장질환 또는 암의 치료 또는 예방을 위한 약제학적 조성물.
- 제36항에 있어서, 암의 치료 또는 예방을 위한 약제학적 조성물.
- 제37항에 있어서, 상기 암이 머리, 목, 눈, 입, 인후, 피하 조직, 림프절, 식도, 흉부, 뼈, 장, 폐, 결장, 직장, 위, 심장, 전립선, 유방, 난소, 부신, 신장, 간, 췌장 또는 뇌의 원발성 또는 전이성 암인 약제학적 조성물.
- 제38항에 있어서, 상기 암이 직장결장암인 약제학적 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42601602P | 2002-11-14 | 2002-11-14 | |
US60/426,016 | 2002-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050086624A KR20050086624A (ko) | 2005-08-30 |
KR100671366B1 true KR100671366B1 (ko) | 2007-01-19 |
Family
ID=32326306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057008631A KR100671366B1 (ko) | 2002-11-14 | 2003-11-13 | 탈리도마이드의 제약 조성물 및 투여 형태 |
Country Status (19)
Country | Link |
---|---|
US (1) | US7230012B2 (ko) |
EP (2) | EP2277512A3 (ko) |
JP (2) | JP5269280B2 (ko) |
KR (1) | KR100671366B1 (ko) |
CN (2) | CN1738607B (ko) |
AU (2) | AU2003290982C1 (ko) |
BR (1) | BR0316240A (ko) |
CA (1) | CA2505964C (ko) |
DK (1) | DK1562556T3 (ko) |
ES (1) | ES2403142T3 (ko) |
HK (1) | HK1088543A1 (ko) |
IL (1) | IL168585A (ko) |
MX (1) | MXPA05005162A (ko) |
NZ (1) | NZ540545A (ko) |
PT (1) | PT1562556E (ko) |
SI (1) | SI1562556T1 (ko) |
TW (2) | TWI377062B (ko) |
WO (1) | WO2004045579A2 (ko) |
ZA (1) | ZA200503927B (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200054046A (ko) | 2018-11-09 | 2020-05-19 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
KR20230068335A (ko) | 2021-11-09 | 2023-05-17 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
WO2023085785A1 (ko) | 2021-11-09 | 2023-05-19 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
KR20240066904A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
KR20240066906A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
ES2629682T3 (es) | 2004-03-29 | 2017-08-14 | University Of South Florida | Tratamiento efectivo de tumores y cáncer con fosfato de triciribina |
US7534381B2 (en) * | 2005-09-14 | 2009-05-19 | Isp Investments Inc. | Process and apparatus for forming agglomerates of a powder composition of an active and binder |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
KR101462693B1 (ko) * | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
EP2091520B1 (en) * | 2006-11-10 | 2012-02-22 | Alphaptose Gmbh | Oral dosage form comprising tri-substituted glycerol compounds |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
MX2011008554A (es) | 2009-05-19 | 2011-10-06 | Celgene Corp | Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il) isoindolin-1,3-diona. |
KR101369936B1 (ko) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물 |
JP5087182B1 (ja) | 2012-06-13 | 2012-11-28 | クリニプロ株式会社 | 吸入用パウダーの製造方法 |
WO2015116802A1 (en) | 2014-01-29 | 2015-08-06 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
CN106137986B (zh) * | 2015-03-09 | 2019-04-16 | 常州制药厂有限公司 | 一种沙利度胺片及其制备方法 |
CN106138052B (zh) * | 2015-04-16 | 2020-02-21 | 欣凯医药化工中间体(上海)有限公司 | 一种沙利度胺制剂及其制备方法 |
CN111107874A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
CN112312904A (zh) | 2018-04-16 | 2021-02-02 | C4医药公司 | 螺环化合物 |
EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
CN113557235A (zh) | 2019-03-06 | 2021-10-26 | C4医药公司 | 用于药物治疗的杂环化合物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5405855A (en) | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US6001828A (en) | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
NZ336035A (en) | 1996-11-05 | 2002-03-28 | Childrens Medical Center | Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug |
CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
NZ521937A (en) * | 2000-03-31 | 2004-08-27 | Celgene Corp | Inhibition of cyclooxygenase-2 activity |
CA2408710C (en) * | 2000-05-15 | 2010-01-26 | Celgene Corp. | Compositions and methods for the treatment of colorectal cancer |
WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2003
- 2003-06-30 US US10/608,077 patent/US7230012B2/en not_active Expired - Lifetime
- 2003-11-13 WO PCT/US2003/036620 patent/WO2004045579A2/en active Application Filing
- 2003-11-13 BR BR0316240-0A patent/BR0316240A/pt not_active IP Right Cessation
- 2003-11-13 CN CN200380108803.9A patent/CN1738607B/zh not_active Expired - Fee Related
- 2003-11-13 EP EP10175930A patent/EP2277512A3/en not_active Withdrawn
- 2003-11-13 DK DK03783567.5T patent/DK1562556T3/da active
- 2003-11-13 ES ES03783567T patent/ES2403142T3/es not_active Expired - Lifetime
- 2003-11-13 JP JP2004553785A patent/JP5269280B2/ja not_active Expired - Lifetime
- 2003-11-13 SI SI200332255T patent/SI1562556T1/sl unknown
- 2003-11-13 PT PT37835675T patent/PT1562556E/pt unknown
- 2003-11-13 MX MXPA05005162A patent/MXPA05005162A/es active IP Right Grant
- 2003-11-13 NZ NZ540545A patent/NZ540545A/en not_active IP Right Cessation
- 2003-11-13 EP EP03783567A patent/EP1562556B1/en not_active Expired - Lifetime
- 2003-11-13 AU AU2003290982A patent/AU2003290982C1/en not_active Expired
- 2003-11-13 CN CN201010115035A patent/CN101816626A/zh active Pending
- 2003-11-13 KR KR1020057008631A patent/KR100671366B1/ko active IP Right Grant
- 2003-11-13 CA CA002505964A patent/CA2505964C/en not_active Expired - Lifetime
- 2003-11-14 TW TW096113473A patent/TWI377062B/zh not_active IP Right Cessation
- 2003-11-14 TW TW092132008A patent/TWI359659B/zh not_active IP Right Cessation
-
2005
- 2005-05-15 IL IL168585A patent/IL168585A/en active IP Right Grant
- 2005-05-16 ZA ZA200503927A patent/ZA200503927B/en unknown
-
2006
- 2006-08-15 HK HK06109062.8A patent/HK1088543A1/xx not_active IP Right Cessation
-
2009
- 2009-05-15 JP JP2009119084A patent/JP4927905B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-13 AU AU2010201931A patent/AU2010201931A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200054046A (ko) | 2018-11-09 | 2020-05-19 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
KR20230068335A (ko) | 2021-11-09 | 2023-05-17 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
WO2023085785A1 (ko) | 2021-11-09 | 2023-05-19 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
KR20240066904A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
KR20240066906A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100671366B1 (ko) | 탈리도마이드의 제약 조성물 및 투여 형태 | |
RU2479307C1 (ru) | Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона | |
EP2651400B2 (en) | Controlled release oral dosage forms of poorly soluble drugs and uses thereof | |
JP5465005B2 (ja) | マントル細胞リンパ腫治療のための3−(4−アミノ−1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−ピペリジン−2,6−ジオンの使用 | |
US9468605B2 (en) | Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | |
US20020128228A1 (en) | Compositions and methods for the treatment of cancer | |
JP2007534632A (ja) | アスベスト関連疾患および障害の治療および管理のための免疫調節化合物の使用方法およびそれを含む組成物 | |
EA027801B1 (ru) | Составы (+)-2-[1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-4-ацетиламиноизоиндолин-1,3-диона | |
KR20030025922A (ko) | 암 치료용 조성물 및 치료 방법 | |
US9006267B2 (en) | Pharmaceutical compositions and dosage forms of thalidomide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141226 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151224 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161230 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 13 |